A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer

被引：0
|
作者：
Yoo, Changhoon [1 ]
Ryu, Min-Hee [1 ]
Ryoo, Baek-Yeol [1 ]
Koo, Dong Hoe [1 ]
Park, Inkeun [1 ]
Kang, Yoon-Koo [1 ]
机构：
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
73
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Mature data on capecitabine (X) plus fractionated cisplatin (P) as first-line therapy in patients (PTS) with advanced gastric carcinoma (AGC)
    Jin, Maolin
    Shen, Lin
    Hu, Bing
    Yu, Jiren
    Wen, Zhaozhang
    Su, Yongqian
    Wang, Baocheng
    Chen, Li
    Yin, Haoran
    Chen, Li
    ANNALS OF ONCOLOGY, 2006, 17 : 317 - 317
  • [42] Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer
    Fizazi, K
    Ducreux, M
    Ruffié, P
    Bonnay, M
    Daniel, C
    Soria, JC
    Hill, C
    Fandi, A
    Poterre, M
    Smith, M
    Armand, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) : 2293 - 2300
  • [43] Dose-finding phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
    Yamazaki, K.
    Kito, Y.
    Esaki, T.
    Satake, H.
    Taniguchi, H.
    Tsuda, T.
    Denda, T.
    Moriwaki, T.
    Mori, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Kang, Y. -K.
    Kang, W. -K.
    Shin, D. -B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Guan, Z.
    Khasanov, R.
    Zheng, L.
    Philco-Salas, M.
    Suarez, T.
    Santamaria, J.
    Forster, G.
    McCloud, P. I.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 666 - 673
  • [45] Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer
    Liu, Chaoying
    Sun, Qing
    Hang, Xiaosheng
    Zhong, Baoliang
    Wang, Daoyuan
    ANTI-CANCER DRUGS, 2008, 19 (08) : 825 - 831
  • [46] A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy.
    Kang, HJ
    Kim, TW
    Chang, HM
    Ryu, MH
    Yook, JH
    Oh, ST
    Kim, BS
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 326S - 326S
  • [47] A phase II study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer.
    Park, Y.
    Lee, J.
    Ryoo, B.
    Ryu, M.
    Yang, S.
    Kim, B.
    Shin, D.
    Chang, H.
    Kim, T.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197S
  • [48] Preliminary results of a dose-finding study of 'Tomudex' with cisplatin and epirubicin as first-line therapy for metastatic or unresectable gastric and oesophageal adenocarcinoma
    Eatock, MM
    Anthony, DA
    Wilson, P
    Soukop, M
    Smith, M
    Evans, TRJ
    ANNALS OF ONCOLOGY, 1998, 9 : 49 - 50
  • [49] Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer
    Vestermark, L.
    Jensen, H.
    Schoennemann, K.
    Krogh, M.
    Pfeiffer, P.
    ANNALS OF ONCOLOGY, 2015, 26
  • [50] Capecitabine (X) combined with cisplatin (P) as 1st-line therapy in Chinese patients (pts) with advanced gastric cancer (AGC).
    Jin, M
    Shen, L
    Hu, B
    Yu, J
    Wen, Z
    Su, Y
    Wang, B
    Chen, L
    Ying, H
    Chen, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 325S - 325S
12345